TORRENT PHARMACEUTICALS LNSE: TORNTPHARMBSE: 500420Healthcare · PharmaceuticalsTORRENT PHARMACEUTICALS L Quarterly Results
In Jun 2026, TORRENT PHARMACEUTICALS L reported revenue of ₹4,921 crore (up 17.3% on the prior quarter) and net profit of ₹566 crore (up 45.5%). 34 reported quarters are tabulated below.
- Latest quarter revenue
- ₹4,921 Cr
- EBITDA
- ₹1,664 Cr
- Operating margin
- 33.81%
- Profit after tax
- ₹566 Cr
- Net margin
- 11.5%
- EPS
- ₹16.72
- Latest quarter
- Jun 2026
- Quarters reported
- 34
TORRENT PHARMACEUTICALS L revenue and profit trend
The quickest view of reported quarterly business performance. Revenue and profit use separate scales.
TORRENT PHARMACEUTICALS L quarterly results
Reported quarterly performance for TORRENT PHARMACEUTICALS L, oldest to newest. Figures in ₹ crore unless a row states otherwise.
| Line item | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| Sales Growth YoY % | 16.11% | 9.67% | 10.2% | 10.34% | 8.61% | 2.82% | 7.8% | 11.16% | 14.3% | 17.59% | 41.84% | 54.85% |
| Other Income | 26 | -33 | 31 | 24 | -16 | 33 | -18 | -37 | -27 | -13 | -17 | -12 |
| Total Income | 2,686 | 2,699 | 2,776 | 2,883 | 2,873 | 2,842 | 2,941 | 3,141 | 3,275 | 3,290 | 4,180 | 4,909 |
| Cost of Goods Sold (COGS) | 660 | 697 | 679 | 694 | 678 | 673 | 731 | 774 | 800 | 799 | 1,015 | 1,163 |
| Cost of Materials Consumed | 433 | 379 | 410 | 411 | 337 | 370 | 402 | 396 | 382 | 414 | 566 | 609 |
| Purchases of Stock-in-Trade | 292 | 327 | 315 | 313 | 382 | 420 | 416 | 338 | 382 | 422 | 477 | 531 |
| Changes in Inventories | -65 | -9 | -46 | -30 | -41 | -117 | -87 | 40 | 36 | -37 | -28 | 23 |
| Gross Profit | 2,000 | 2,035 | 2,066 | 2,165 | 2,211 | 2,136 | 2,228 | 2,404 | 2,502 | 2,504 | 3,182 | 3,758 |
| Gross Margin % | 75.19% | 74.49% | 75.26% | 75.73% | 76.53% | 76.04% | 75.3% | 75.65% | 75.77% | 75.81% | 75.82% | 76.37% |
| Total Operating Expenses | 1,175 | 1,166 | 1,183 | 1,261 | 1,272 | 1,222 | 1,264 | 1,372 | 1,419 | 1,416 | 1,826 | 2,094 |
| Employee Benefit Expense | 503 | 496 | 486 | 550 | 543 | 549 | 561 | 605 | 627 | 651 | 788 | 893 |
| Other Expenses | 672 | 670 | 697 | 711 | 729 | 673 | 703 | 767 | 792 | 765 | 1,038 | 1,201 |
| EBITDA | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 |
| OPM % | 31.02% | 31.81% | 32.17% | 31.62% | 32.5% | 32.54% | 32.58% | 32.47% | 32.8% | 32.94% | 32.31% | 33.81% |
| Total Non-Operating Expenses | 292 | 381 | 283 | 272 | 262 | 256 | 233 | 257 | 239 | 241 | 678 | 877 |
| Depreciation & Amortisation | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 |
| Finance Costs | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 |
| Exceptional Items (Before Tax) | 0 | 88 | 0 | 0 | 0 | 0 | -24 | 0 | -13 | -10 | -66 | -21 |
| Profit Before Tax (PBT) | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 |
| Tax Expense | 173 | 188 | 182 | 199 | 208 | 188 | 167 | 190 | 200 | 179 | 165 | 167 |
| Current Tax | 120 | 106 | 142 | 126 | 156 | 153 | 184 | 201 | 233 | 244 | 166 | 254 |
| Deferred Tax | 53 | 82 | 40 | 73 | 52 | 35 | -17 | -11 | -33 | -65 | -1 | -87 |
| Effective Tax % | 30.95% | 29.79% | 28.84% | 30.34% | 31.47% | 27.21% | 25.11% | 25.75% | 25.28% | 21.99% | 31.19% | 22.78% |
| Total Profit for Period | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 |
| Less: Non-controlling Interests | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25 | 0 |
| Net Profit (Owner's PAT) | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 389 | 566 |
| Net Profit Margin % | 14.51% | 16.22% | 16.36% | 15.98% | 15.68% | 17.91% | 16.83% | 17.24% | 17.9% | 19.22% | 9.27% | 11.5% |
| PAT Growth YoY % | 23.72% | 56.54% | 56.45% | 20.9% | 17.36% | 13.54% | 10.91% | 19.91% | 30.46% | 26.24% | -21.89% | 3.28% |
| Earnings Per Share (EPS) | ₹11.41 | ₹13.09 | ₹13.27 | ₹13.5 | ₹13.38 | ₹14.86 | ₹14.71 | ₹16.19 | ₹17.46 | ₹18.76 | ₹11.49 | ₹16.72 |
| Diluted Shares Outstanding (Cr.) | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 |
| Other Comprehensive Income (Net of Tax) | -23 | -1 | 1 | -34 | -25 | -70 | 36 | -2 | -76 | -16 | -86 | 79 |
| Expenses | 2,127 | 2,068 | 2,145 | 2,227 | 2,212 | 2,151 | 2,276 | 2,403 | 2,484 | 2,476 | 3,651 | 4,176 |
| Material Cost % | 16.28% | 13.87% | 14.94% | 14.38% | 11.66% | 13.17% | 13.59% | 12.46% | 11.57% | 12.53% | 13.49% | 12.38% |
| Employee Cost % | 18.91% | 18.16% | 17.7% | 19.24% | 18.8% | 19.54% | 18.96% | 19.04% | 18.99% | 19.71% | 18.78% | 18.15% |
| Other Cost % | 25.26% | 24.52% | 25.39% | 24.87% | 25.23% | 23.96% | 23.76% | 24.13% | 23.99% | 23.16% | 24.73% | 24.41% |
| Interest Coverage (x) | 6.86 | 8.2 | 8.5 | 9.43 | 11.58 | 12.54 | 13.63 | 14.84 | 18.31 | 19.6 | 3.59 | 3.51 |
Showing the most recent 12 of 34 reported periods.
How this is calculated
Figures are as reported to NSE/BSE by the company. Consolidated is shown where the company reports it, standalone otherwise; the basis is labelled on the table. Growth is computed against the same quarter of the previous year (YoY) and the immediately preceding quarter (QoQ).
Index membership reflects the Nifty 100 as published by NSE Indices, effective 2026-03-30.
TORRENT PHARMACEUTICALS L: frequently asked questions
What was TORRENT PHARMACEUTICALS L's revenue in Jun 2026?
TORRENT PHARMACEUTICALS L reported revenue of ₹4,921 crore in Jun 2026, up 17.3% on the previous quarter.
What was TORRENT PHARMACEUTICALS L's profit in Jun 2026?
TORRENT PHARMACEUTICALS L reported a net profit of ₹566 crore in Jun 2026, up 45.5% on the previous quarter.
What is TORRENT PHARMACEUTICALS L's EPS?
TORRENT PHARMACEUTICALS L reported earnings per share of ₹16.72 for Jun 2026.
What is TORRENT PHARMACEUTICALS L's operating margin?
TORRENT PHARMACEUTICALS L's operating margin for Jun 2026 was 33.81%.
When did TORRENT PHARMACEUTICALS L last report results?
The most recent reported quarter shown here is Jun 2026. 34 quarters of history are tabulated on this page.
Are these figures consolidated or standalone?
Consolidated figures are shown wherever the company reports them, and standalone otherwise. The basis in use is labelled on the statement table.
More TORRENT PHARMACEUTICALS L data
Compare quarterly results with peers
Comparing quarterly results across companies is more useful than reading one in isolation — the peer links above open the same view for TORRENT PHARMACEUTICALS L’s closest listed competitors.
The data, ratios and commentary about TORRENT PHARMACEUTICALS L (TORNTPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.